Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?

Recent trials have demonstrated that the addition of a programmed cell death protein 1 inhibitor to chemotherapy in the first-line setting in patients with metastatic squamous or nonsquamous non-small cell lung cancer improves survival compared with chemotherapy alone. These findings provide a new treatment option for patients with newly diagnosed, advanced non-small cell lung cancer, regardless of tumor histology or programmed death-ligand 1 expression, thereby representing a major advancement in the field.